Autopsy report · NCT03369912

A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

“Company decision to withdraw before study started”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 2

Sponsor

Novartis Pharmaceuticals

Sponsor type

Industry

Conditions

HCMV Infection

Interventions

CSJ148; Placebo

Participants

0

Trials that died the same way

• Dose Ranging Study to Evaluate the Efficacy and Safety of MEDI8852 in Adults Who Are Hospitalized With Type A Influenza.
  “Study is withdrawn due to company decision.” (84% match in meaning)
• Group Education & Lifestyle Modification's Impact on Weight Loss & Quality Life of Patients with OA
  “Investigator decision to withdraw study.” (79% match in meaning)
• ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma
  “Study withdrawn before opening to accrual.” (78% match in meaning)
• A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a
  “Sponsor decision to withdraw study at this time.” (77% match in meaning)
• A Study of Glucose Control in Participants With Type 1 and Type 2 Diabetes
  “Study was withdrawn prior to enrolment due to business decision.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.